Table 1

Baseline characteristics by treatment group

Salmeterol+ ipratropium bromide (n=47)Salmeterol+ placebo (n=47)Placebo+ placebo (n=50)p value1-150
Age (years)63.0 (7.1)65.4 (5.8)63.2 (7.4)0.165
Years since onset of COPD11.2 (10.0)12.4 (10.7)13.8 (11.0)0.511
Sex (% male)87.2%89.4%86.0%0.880
Pre-bronchodilator FEV1 (l)1.4 (0.4)1.3 (0.4)1.3 (0.4)0.649
FEV1 (% predicted)44.7 (11.3)44.0 (9.6)42.0 (10.8)0.447
FVC (l)3.1 (0.8)2.9 (0.7)3.0 (0.7)0.432
PEFR (l/s)279 (89)267 (75)264 (81)0.624
Reversibility (% predicted)6.7 (4.6)5.7 (4.2)5.8 (3.1)0.385
Using inhaled steroids (%)7481760.743
On salmeterol before start of the run in (%)5757510.791
SGRQ:Total48.3 (13.9)50.5 (16.6)50.2 (15.8)0.640
 Symptoms54.0 (19.9)52.7 (25.5)54.4 (22.6)0.936
 Activities64.0 (14.8)65.7 (17.5)64.5 (17.2)0.879
 Impact37.2 (16.6)42.2 (18.6)40.9 (18.1)0.387
CRQ: Total4.44 (0.81)4.58 (1.03)4.22 (1.05)0.241
 Dyspnoea3.21 (0.99)3.64 (1.19)3.45 (1.14)0.331
 Fatigue4.35 (1.06)4.33 (1.16)4.11 (1.19)0.553
 Emotions4.87 (1.00)5.00 (1.10)4.45 (1.28)0.056
 Mastery5.31 (1.22)5.26 (1.27)4.92 (1.40)0.278
  • Data are presented as mean (SD) unless otherwise stated.

  • FEV1 = forced expiratory volume in one second; FVC = forced vital capacity; PEFR = peak expiratory flow rate; SGRQ = St George’s Respiratory Questionnaire; CRQ = Chronic Respiratory Disease Questionnaire.

  • 1-150 ANOVA on means of three groups and χ2 for proportions.